Genetic alterations of APC and CTNNB1 (b-catenin) have been identified in a number of human cancers including tumors arising in the colon and liver. Mutations in these genes lead to abnormal accumulation of b-catenin and constitutive activation of target genes in the Wnt signaling pathway. To clarify the precise role of accumulated bcatenin in colorectal carcinogenesis, we searched for genes involved in the b-catenin/Tcf signaling pathway by cDNA microarray. MT1 -MMP (membrane-type matrix metalloproteinase) was among 84 genes that were downregulated after b-catenin had been depleted by transduction of wild-type APC in SW480 cells. Expression of MT1 -MMP was elevated in 22 of 24 colon carcinomas we examined. Reporter assays and an electromobility-shift assay revealed a DNA fragment between 71169 bp and 71163 bp in the 5' flanking region of this gene to be a target of the b-catenin/Tcf4 complex. Our results indicate that MT1 -MMP is a direct down-stream target in the Wnt signaling pathway, and that one of the ways accumulated b-catenin contributes to colorectal carcinogenesis is by transactivating this gene.
Introduction
Studies of hereditary and sporadic colorectal tumors at the molecular level have disclosed that impaired Wnt signaling characterizes early steps as well as progression of colorectal carcinogenesis. APC, the tumor suppressor gene responsible for familial adenomatous polyposis coli, is also frequently mutated in sporadic colon tumors, gastric cancers, and desmoid tumors. APC forms a multi-molecular complex with b-catenin, Axin/Conductin and glycogen synthase kinase 3b in order to down-regulate b-catenin, which is a key mediator of the Wnt signaling pathway (Rubinfeld et al., 1996; Yamamoto et al., 1999) . Since most APC mutations in colorectal tumors produce truncated proteins lacking domains for binding b-catenin and/or Axin, mutant APC protein cannot form the degradation complex; under these circumstances b-catenin accumulates in the cytoplasm and/or nucleus Morin et al., 1997; Nakamura et al., 1998; Yamamoto et al., 1999) . Some colon cancers harbor mutations in the b-catenin gene (CTNNB1) itself, around sequences in exon 3 encoding serine/threonine phosphorylation residues, and the mutant b-catenin products are refractory to degradation. Accumulated b-catenin forms a complex with the Tcf/LEF transcription factor and up-regulates target genes such as c-myc (He et al., 1998), cyclinD1 (Tetsu and McCormick, 1999) , MMP-7 (matrilysin) (Brabletz et al., 1999; Crawford et al., 1999) , urokinase-type plasminogen activator receptor (uPAR) (Mann et al., 1999) , connexin 43 (van der Heyden et al., 1998) , CD44 (Wielenga et al., 1999) , PPAR -delta (He et al., 1999) , AF17 (Lin et al., 2001) , ENC1 , Laminin-5 g2 (Hlubek et al., 2001) and Claudin-1 .
Matrix metalloproteinases (MMPs) were initially characterized by their ability to degrade various components of the extracellular matrix (ECM). MMP-2 (gelatinase A), the most abundant MMP, is activated through processing of proMMP-2 by membrane-type MMPs (Nagase and Woessner, 1999; Seiki, 1999) . Another member of the MMP family, MT1 -MMP (MMP-14), contains a transmembrane/ cytoplasmic sequence that confines it to microinvasion sites on the surface of tumor-cell invadopodia (Nakahara et al., 1997) , where it acts as a receptor and activates MMP-2 in a complex with TIMP2 (tissue inhibitor of metalloproteinases 2) (Kinoshita et al., 1998) . MT1 -MMP also degrades collagen types I, II and III, fibronectin, laminin 1 and 5, vitronectin, aggrecan, CD44, and proMMP-13 (procollagenase3) (Buttner et al., 1998; Cowell et al., 1998; d'Ortho et al., 1997; Fosang et al., 1998; Kajita et al., 2001; Knauper et al., 1996; Koshikawa et al., 2000; Ohuchi et al., 1997) . MT1 -MMP is often over-expressed in human tumors arising in the colon, breast, ovary, esophagus, skin, liver, head and neck, or brain; its elevated expression has been associated with tumor invasion (Seiki, 1999) and/or lymph node metastasis (Imanishi et al., 2000) . However, the mechanisms responsible for the heightened expression levels remain unclear.
To shed light on the effect(s) of abrogated Wnt signaling in colorectal tumors, we previously developed a system for screening transcriptional targets of the bcatenin/Tcf4 complex in SW480 colon cancer cells. Here we report identification of MT1 -MMP as a direct down-stream target of this complex, and discuss the possible roles played by MT1 -MMP in human colorectal carcinogenesis.
Results

Increased expression of MT1 -MMP in colorectal-cancer tissues
It has previously been reported that adenovirusmediated gene transfer of the 20-amino-acid-repeat region of APC reduced nuclear levels of b-catenin in SW480 cells (Munemitsu et al., 1995) , leading in turn to decreased transcriptional activity of Tcf4. Among 23 040 genes on our cDNA microarray slides, we identified 84 genes that were down-regulated in response to transduction of the APC gene (Lin et al., 2001) . Among the 84 genes, we focused on MT1 -MMP, since another matrix -metalloproteinase gene, MMP7, was reported as a direct target of b-catenin/Tcf4 (Brabletz et al., 1999; Crawford et al., 1999) , and elevated expression of MT1 -MMP had previously been reported in colon cancer. Semi-quantitative RT -PCR revealed that its expression decreased significantly with the addition of wild-type APC or a dominant-negative form of Tcf4 ( Figure 1A ). Further comparisons of expression patterns of these 84 genes in colorectal-cancer samples versus their corresponding non-cancerous tissues revealed elevated expression of MT1 -MMP in 22 (92%) of the 24 cancerous tissues examined (Figure 1b) . These data strongly suggested that expression of MT1 -MMP is regulated by b-catenin, because accumulation of bcatenin is observed in a majority of colorectal cancers as a consequence of mutations in APC or CTNNB1.
Immunohistochemical staining
To examine whether expression of MT1 -MMP was elevated in tumor cells or stromal cells in colorectal cancers, we carried out immunohistochemical staining of MT1 -MMP ( Figure 2A ) and b-catenin ( Figure 2B ) in 13 colorectal cancer tissues. In 12 of the 13 cases examined, immunohistochemical staining revealed high levels of b-catenin accumulation in the cytoplasm and/ or nuclei predominantly among cancerous cells. High levels of MT1 -MMP staining was also observed in the cytoplasm of cancerous cells, although weaker staining could be detected in stromal cells and non-cancerous epithelial cells. In the single case where b-catenin had not accumulated, expression of MT1 -MMP was not elevated either. These data corroborated the positive correlation between expression of MT1 -MMP and accumulation of b-catenin.
Identification of a Tcf/LEF target site in the MT1 -MMP promoter
To investigate whether MT1 -MMP is a direct transcriptional target of the b-catenin/Tcf4 complex, we searched for the consensus Tcf4-binding motif, 5'-CTTTGWW-3', in the 5' flanking region of MT1 -MMP. By searching public databases we obtained genomic sequences corresponding to MT1 -MMP (GenBank accession number AL135998). Within a 2-kb genomic fragment upstream from the translationinitiation site we identified two possible Tcf4-binding motifs, one between 71169 and 71163 (TBM1), and the other between 7576 and 7570 (TBM2; Figure  3A ). To test whether these binding motifs could affect the promoter activity of MT1 -MMP, various parts of the 5' flanking region were cloned upstream of the luciferase gene, and reporter assays were carried out ( Figure 3B ). Construct P1, containing both TBM1 and 72 revealed a 300-fold increase in luciferase activity compared to either P2 (containing TBM2 alone) or P3 (lacking both TBM1 and 72). To test the functional significance of the binding motifs, we introduced mutations in the putative binding sequences (CTTTGWW to CTTTGGC) by site-directed mutagenesis (He et al., 1998) . Introduction of the mutation into TBM1 (P1m1) reduced the luciferase activity by more than 70%, whereas the mutation at TBM2 (P1m2) had no significant effect. These results suggested that the TBM1 motif is responsible for the promoter activity of MT1 -MMP.
We also transfected HeLa cells with constructs P1 and P1m1 with or without an activated form of mutant b-catenin, in combination with wild-type or a dominant-negative form of Tcf4 ( Figure 3C ). Only the reporter activity of P1 was significantly enhanced by introduction of activated b-catenin and wild-type Tcf4. This activity was reduced when P1 was co-transfected with dominant-negative Tcf4.
MT1 -MMP as a direct target of Tcf/LEF
To examine whether the b-catenin/Tcf4 complex could associate with the binding motif in the promoter region of MT1 -MMP, we carried out an electrophoretic mobility-shift assay (EMSA) using oligonucleotides encompassing the TBM1 sequence. A single band was shifted by addition of anti-b-catenin antibody, but not by an unrelated (control) antibody. This binding was abrogated by addition of wild-type unlabeled oligonucleotides, but not by mutant unlabeled oligonucleotides (Figure 4 ).
Discussion
Deregulation of the Wnt signaling pathway appears to be an essential early event in colorectal carcinogenesis, since mutations of APC are often detected in small adenomas. Moreover, since the degree of nuclear staining of b-catenin correlates with tumor size and dysplasia, and since high levels of b-catenin are detected at invasion fronts of colon cancers, nuclear accumulation of b-catenin is thought to be involved in progression from the adenoma stage to invasive carcinoma. Among known downstream targets of the b-catenin/Tcf4 complex, c-myc, cyclinD1 and AF17 play roles in proliferation, transformation, and/or deregulation of the cell cycle. Other target genes such as MMP-7, CD44, uPAR, Laminin-5 g2, and Claudin-1 may be involved in initiation and/or progression of colorectal tumors. In the study presented here, we have established a positive correlation between expression of MT1 -MMP and accumulation of bcatenin in SW480 cell line and in primary colorectal cancers. Furthermore, we have clearly demonstrated that a putative Tcf4-binding sequence in the 5' flanking region of MT1 -MMP is responsible for its promoter activity, and that this motif associates directly with the b-catenin/Tcf4 complex. These data indicated that MT1 -MMP is a direct transcriptional target of this complex.
MMP-7, another target of b-catenin/Tcf4, is expressed in more than 90% of colorectal carcinomas and also in colorectal adenomas, where it contributes to tumor formation and progression (Yoshimoto et al., 1993; Newell et al., 1994) . MT1 -MMP was Figure 2 Immunohistochemical staining of MT1 -MMP (A) and b-catenin (B) in cancerous and non-cancerous cells from human colon. Immunostaining revealed MT1 -MMP to be localized predominantly in the tumor-cell cytoplasm but also in the stroma, while b-catenin was stained in both cytoplasm and nuclei of tumor cells (640) originally identified as an activator of MMP-2, which plays a role in degradation of type-IV collagen, a major component of basement membrane (Sato et al., 1994) . MT1 -MMP recruits TIMP-2 for activation of proMMP-2, a process enhanced by claudins 71, 72, 73 and 75 (Miyamori et al., 2001) . MT1 -MMP also activates proMMP-13 and degrades collagens type I, II, III, V, VII and X, fibronectin, vitronectin, and Laminins 1 and 5 (Knauper et al., 1996; Koshikawa et al., 2000; Ohuchi et al., 1997) . Overexpression of MT1 -MMP has enhanced pulmonary metastasis in animal models (Tsunezuka et al., 1996) and the invasiveness of MDCK cells in other experiments (Hotary et al., 2000) . Expression of MT1 -MMP is associated with invasion and/or metastasis of human cancers (Harada et al., 1998; Kikuchi et al., 2001; Mimori et al., 2001; Shimada et al., 2000) , and it also plays a role in cell motility mediated by CD44-shedding (Kajita et al., 2001) . It is noteworthy that Claudin-1, Laminin-5 g2 and CD44 are also up-regulated by the b-catenin/Tcf4 complex Hlubek et al., 2001; Wielenga et al., 1999) . These data underscore the importance of MT1 -MMP in colorectal carcinogenesis and may imply that activated b-catenin/Tcf4 signaling may enhance cell motility, invasion, and/or metastasis through cooperation of MT1 -MMP with Claudin-1, Laminin-5 g2, and CD44.
Although elevated expression of MT1 -MMP mRNA was first detected in human cancers by in situ hybridization in stromal fibroblasts near invading cancer cells, but not in the carcinoma cells (Okada et al., 1995) , the precise localization remains controversial. A recent report showed that MT1 -MMP expression was only evident in the fibroblastic cells of cancer tissues from colon, breast, prostate and ovary, according to results of immunohistochemical staining with anti-MT1 -MMP antibodies (Nelson et al., 2000) . In contrast, others have demonstrated that in hepatocellular carcinomas, oral cancers, head and neck cancers, breast cancers, and ovarian cancers, MT1 -MMP was mainly expressed in cancer cells but also appeared in stromal cells (Afzal et al., 1998; Imanishi et al., 2000; Ishigaki et al., 1999; Shimada et al., 2000) . Recently Kikuchi et al. (2001) observed the presence of MT1 -MMP in cancer cells in nearly one-third of the 92 human colorectal cancers they examined by immunohistochemical staining. We also observed positive staining in cancer cells but at a much higher frequency, a result that could reflect different sensitivities of the antibodies used. Our staining also revealed that some cells with accumulated b-catenin were negative for MT1 -MMP, which suggests that factors other than b-catenin may influence the expression levels of MT1 -MMP. Since accumulation of b-catenin in the cytoplasm and/or nucleus is a common feature of colorectal cancers, frequent up-regulation of MT1 -MMP is in good agreement with the notion that its expression is regulated by b-catenin. Although high levels of MT1 -MMP expression were previously reported in the invading region of L-10 rectal-cancer cells activated by hepatocyte growth factor (Nabeshima et al., 2000) , in our experiments staining was no stronger in the invading front than in the tumor cells behind it. These results may imply that enhanced expression of MT1 -MMP plays a role not only in invasion but also in earlier steps. In line with this view, transgenic mice that over-express MT1 -MMP in mammary glands frequently develop various types of mammary tumors including adenocarcinomas (Ha et al., 2001) . Further studies should focus on expression of this gene in various stages of colorectal carcinogenesis, to clarify the precise role of MT1 -MMP in this type of tumor.
Elevated expression of MT1 -MMP occurs in gliomas and in cancers arising in the colon, breast, esophagus, ovary, liver, skin, or head and neck, but among these various tissues accumulation of b-catenin is observed most often in colorectal cancers and hepatocellular carcinomas. This suggests that factors other than b-catenin can affect the promoter activity of MT1 -MMP. For example, the 5' flanking region of the MT1 -MMP gene contains one Sp-1 site and four CAAT-boxes, and the Sp-1 binding site plays a crucial role in its expression (Lohi et al., 2000) . Investigation of the mechanisms of transcription, translation, and degradation of MT1 -MMP should eventually provide a more profound understanding of how this protein is regulated.
Since progression of colon cancers involves interference in the microenvironment between tumor and host, targeting this interaction is a rational therapeutic strategy (Brown and Giavazzi, 1995) . Several MMP inhibitors such as COL-3, a tetracycline derivative, are undergoing clinical trials (Rudek et al., 2001) . In mice, MMI-166 has shown high selectivity by inhibiting only MMPs 2, 9 and 14, but not MMPs 1, 3 or 7, and may have therapeutic potential as an anti-metastasis agent (Maekawa et al., 2000) . Since elevated expression of MT1 -MMP appears to play a crucial role in the progression of colorectal cancers, development of specific inhibitors for its protein product should lead to effective agents for treatment of this common type of tumor.
Materials and methods
Cells and tissue specimens
Human colon-cancer cell line SW480 and a human cervix cancer cell line HeLa were obtained from the American Type Culture Collection (ATCC). Cells were cultured as monolayers in appropriate media, i.e. Leibovitz's L-15 media (Life Technologies, Grand Island, NY, USA) for SW480 and Minimum Essential Medium Eagle (Life Technologies) for HeLa, each supplemented with 10% fetal bovine serum and 1% antibiotic/antimycotic solution (Sigma). Cells were maintained at 378C in an atmosphere of humidified air with 5% CO 2 for HeLa and without CO 2 for SW480. Cancerous colonic tissues and corresponding non-cancerous mucosae were excised from 24 patients during surgery with informed consent.
Luciferase assay
Two potential binding sites for Tcf-4, whose consensus target sequence is 5'-CTTTGWW-3', were identified in the 5' flanking region of MT1 -MMP, between 71169 and 71163 (TBM1) and between 7576 and 7570 (TBM2). A wild-type reporter plasmid (P1) containing both TBM1 and 72, as well as two deletion constructs of the plasmid (P2 and P3) were prepared by cloning each sequence into the appropriate enzyme sites of pGL3-Basic Vector (Promega). Plasmids P1, P2 and P3 were constructed by amplification of P1-F (5'-TTGATCATGAATCTGAGGGCAAAAG-3'), P2-F (5'-CAATAATTTCACCCAACTTGATTTGC-3') or P3-F (5'-GAGCCACAGATCCGGTATGGTTG-3'), with the same reverse primer (P1-R; 5'-CTTTGTCTTCGGTAGGCACT-GAAC-3'). Site-directed mutagenesis was carried out for both putative Tcf-4 binding sites, replacing CTTTGWW by CTTTGGC using the QuickChange Site-Directed Mutagenesis Kit according to the supplier's recommendations (Stratagene). A plasmid expressing a dominant-negative form of Tcf4 was prepared as described elsewhere .
Each reporter plasmid (4 mg) was co-transfected with 0.5 mg of pRL -TK plasmid (Promega) using FuGENE6 Reagent (Boehringer) according to the manufacturer's instructions. Luciferase assays were carried out using a Dual-Luciferase Reporter Assay System (Promega) following the manufacturer's protocol.
Electrophoretic mobility-shift assay (EMSA)
The EMSA was performed as previously described (Satoh et al., 2000) using nuclear extracts from SW480 cells. A doublestranded 16-nucleotide DNA probe was prepared by annealing MMP14FF (5'-ACCTTTGGCTTCATTA-3') to MMP14RR (5'-TAATGAAGCCAAAGGT-3'), and labeled with 32 P-gATP and T4 polynucleotide kinase.
Immunohistochemistry
Immunohistochemical staining was carried out using anti-MT1 -MMP antibody (Chemicon catalog number AB815) or anti-b-catenin antibody (Transduction Laboratories). Paraffin-embedded tissue sections were subjected to the SAB-PO peroxidase immunostaining system (Nichirei, Tokyo, Japan) according to the manufacturer's recommended method. Antigens were retrieved from deparaffinized and re-hydrated tissues by pre-treating the slides in citrate buffer (pH6) in a microwave oven for 10 min at 700 W.
